Key result
PCSK9 inhibitor discontinuation is linked to ~86% higher major cardiovascular events risk in CAD patients.
Why the study?
The clinical consequences of discontinuing PCSK9 inhibitors in patients with coronary artery disease have not been elucidated.
Does discontinuation of PCSK9 inhibitors increase major adverse cardiovascular events in patients with coronary artery disease?
Observational (n=208)
Yes
Does discontinuation of PCSK9 inhibitors increase major adverse cardiovascular events in patients with coronary artery disease?
Discontinuation of PCSK9 inhibitors in patients with coronary artery disease is associated with a significant increase in long-term cardiovascular risk, highlighting the importance of sustained lipid-lowering therapy.
Answers are grounded in this paper and cite their sources.
May warrant caution with PCSK9 inhibitor discontinuation in CAD; leaves open causality and need for randomized confirmation.
BACKGROUND: The clinical consequences of discontinuing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been elucidated. METHODS AND RESULTS: We analyzed 208 patients with coronary artery disease treated with PCSK9 inhibitors. During a median follow-up of 1,096 days, 94 patients discontinued treatment and they had a higher incidence of major adverse cardiovascular events (MACE) than those who continued. Event curves diverged approximately 3 years after discontinuation. Multivariable Cox analysis showed that discontinuation was associated with a higher incidence of MACE. CONCLUSIONS: Discontinuation of PCSK9 inhibitors was associated with worse cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Tsubata et al. (2026) conducted an observational in Coronary artery disease (n=208). Discontinuation of PCSK9 inhibitors vs. Continuation of PCSK9 inhibitors was evaluated on Major adverse cardiovascular events (MACE: all-cause death, non-fatal myocardial infarction, stroke or coronary revascularization) (HR 1.86, 95% CI 1.00-3.16, p=0.048). Discontinuation of PCSK9 inhibitors in patients with coronary artery disease was independently associated with an increased risk of major adverse cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: